With the rapid spread of information across the globe, increased communication across borders, increasing public expectation of safety and improved global access to drugs, the challenges associated as well as the importance of pharmacovigilance has never been greater. In this short and sweet interactive overview of the Top 5 Challenges of Pharmacovigilance we not only outline the major PHCV obstacles PHCV leaders currently face but also demonstrate how the 2018 Pharmacovigilance Summit taking place 26-28 February, 2018 in Boston, MA can help you overcome them.
To receive this piece via email, please contact us at firstname.lastname@example.org with "Top 5 Challenges of PHCV Content Request - 20526.003" listed in the subject line.
Since the early 1990s, the FDA has used data mining (the practice of examining large databases to generate new information) to gain a better understanding of adverse signals within clinical trial safety data. The agency has also advocated the use of data mining by the pharmaceutical industry when conducting clinical trials. Recently, the FDA has begun adding more sophisticated methods to its data mining activities and has applied these methods to other product-safety-related databases.
In an effort to define its data mining activities, the FDA has issued a white paper, Data Mining at FDA (Nov 2015). It provides an overview of its past and present data mining methods, the advantages/challenges of data mining and future directions for data mining at the FDA.
Dr. Sameer Thapar, Director, Global Pharmacovigilance (Oracle Health Sciences Consulting), and Assistant Professor, Drug Safety and Pharmacovigilance (Rutgers University), has studied this paper and offered highlights in a new Oracle Brief.
Introduction by Barbara Rudolph, Senior Content Marketing Manager, Oracle